Three years of erlotinib in routine practice for non-small cell lung cancer in South East Scotland

Clinical Oncology : a Journal of the Royal College of Radiologists
J A D IronsideM J Mackean

Abstract

We present a review of 111 patients who were treated over an initial 3-year period with erlotinib. The median treatment time was 68 days and 59% of patients had stopped treatment within the first 3 months. However, 20 patients were on erlotinib for more than 12 months. Performance status and smoking history were the significant prognostic factors. The overall 3-year survival in patients who had never smoked was 26%.

References

Jul 27, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Roy S HerbstUNKNOWN TRIBUTE Investigator Group
Jun 1, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Federico CappuzzoMarileila Varella-Garcia
Aug 21, 2009·The New England Journal of Medicine·Rafael RosellUNKNOWN Spanish Lung Cancer Group

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carcinoma, Squamous Cell

Basal cell carcinoma is a form of malignant skin cancer found on the head and neck regions and has low rates of metastasis. Discover the latest research on basal cell carcinoma here.

Related Papers

The European Respiratory Journal
Elisabeth QuoixIntergroupe Francophone de Cancérologie Thoracique
European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)
M M VickersM J Moore
© 2021 Meta ULC. All rights reserved